This study examined the ability of two widely used "point of care" platelet function assays, VerifyNow and Multiplate, to predict adverse outcomes in patients with acute coronary syndromes (ACS).We examined platelet reactivity using VerifyNow and Multiplate P2Y12 assays in patients with ACS and the relationship between platelet reactivity and both MACE (defined as a composite of death, myocardial infarction, stroke, stent thrombosis and unplanned revascularisation) and TIMI major bleeding at 1year.In 619 ACS patients, 65 patients (10.5
作者：Peter D, Larsen；Ana S, Holley；Alexander, Sasse；Ali, Al-Sinan；Sarah, Fairley；Scott A, Harding
来源：Thrombosis research 2017 年 152卷
